Arundic acid (AA; ONO-2506), a novel modulator of astrocyte activation, may improve neuronal survival after stroke. We conducted a multicenter, dose-escalating, randomized, double-blind Phase I trial of AA in acute ischemic stroke. Subjects were randomized to treatment with AA or placebo in sequential dose tiers of 2-12 mg/kg/h (10-16 patients/group) within 24 h of stroke onset. Study drug was infused for 1 h daily over 7 days, and follow-up terminated at 40 days. Neurological and functional outcomes were evaluated through Day 40 as exploratory endpoints. A total of 92 subjects were enrolled with no dose-related pattern of serious adverse events (AEs). Premature terminations caused by AEs occurred in four (8.2%) patients treated with AA and five (11.6%) treated with placebo. Two subjects treated with AA (4.1%) and four given placebo (9.3%) died. Exploratory efficacy analysis showed a trend toward improvement in the change from baseline National Institutes of Health Stroke Scale (NIHSS) in the 8 mg/kg/h AA group on Days 3 (p = 0.023 vs. placebo), 7 (p = 0.002), 10 (p = 0.003), and 40 (p = 0.018). A dose of 8 mg/kg/h AA produced a favorable trend in reduction of NIHSS that should be confirmed in a future clinical trial.
|Number of pages||7|
|Journal||Journal of the Neurological Sciences|
|State||Published - Dec 21 2006|
Bibliographical noteFunding Information:
Financial support was provided by Ono Pharma USA Inc., Lawrenceville, NJ, as a grant awarded to each participating center and by NIH M01 RR02602 (University of Kentucky General Clinical Research Center). We thank Sherry Chandler Williams, E.L.S., for manuscript preparation and editing.
- Arundic acid
- NIH Stroke Scale
ASJC Scopus subject areas
- Clinical Neurology